Log in

Relevant bibliographies by topics / Pre-Clinical tumor model / Journal articles

To see the other types of publications on this topic, follow the link: Pre-Clinical tumor model.

Journal articles on the topic 'Pre-Clinical tumor model'

Author: Grafiati

Published: 23 November 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pre-Clinical tumor model.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Buxbaum, C., A. Deo, B. Manobla, S. Levin, S. Ash, and Y. Shaked. "P16.07.A STUDYING NEUROBLASTOMA TUMOR MICROENVIRONMENT THROUGH A NOVEL PRE-CLINICAL MODEL." Neuro-Oncology 26, Supplement_5 (2024): v85. http://dx.doi.org/10.1093/neuonc/noae144.282.

Full text

Abstract:

Abstract BACKGROUND Neuroblastoma is a pediatric cancer that develops from neural crest cells. It has a dramatically variable course, ranging from very aggressive disease to benign differentiation and even spontaneous regression. In neuroblastoma, a crucial prognostic marker is the distinct cutoff at 18 months of age. Thus, children older than 18 months have a significantly worse prognosis than younger children. This age cutoff was studied thoroughly, but no explanatory mechanism has been found. All current pre-clinical research encompasses models in adult subjects while the development of tum

APA, Harvard, Vancouver, ISO, and other styles

2

Becker, William J., Purevdorj B. Olkhanud, and Jay A. Berzofsky. "Triple synergy between vaccine and checkpoint inhibitors in a pre-clinical tumor model." Journal of Immunology 208, no. 1_Supplement (2022): 118.14. http://dx.doi.org/10.4049/jimmunol.208.supp.118.14.

Full text

Abstract:

Abstract Despite advances in checkpoint inhibitor (CPI) therapy for cancer treatment, many malignancies remain resistant. Tumors deemed ‘cold’ based on lack of T cell infiltration into the stroma of the tumor show reduced potential for CPI therapy and finding the right combination to balance safety and efficacy is arduous. To study ways to circumvent these limitations, we used the preclinical mouse model of TC1 tumor cells resistant to conventional CPI therapy. The TC1 cells are transfected with oncogenes E6 and E7 of HPV16, and we designed a tumor-vaccine specific for an E7(43–77) peptide. We

APA, Harvard, Vancouver, ISO, and other styles

3

Ernst, Kati, Konstantin Okonechnikov, Laura von Soosten, et al. "BIOL-07. DISTINCTIVE FEATURES OF HIGH-GRADE GLIOMA MOUSE MODELS REVEALED BY SINGLE-NUCLEUS RNA-SEQUENCING GUIDE PRE-CLINICAL MODEL SELECTION." Neuro-Oncology 25, Supplement_1 (2023): i7. http://dx.doi.org/10.1093/neuonc/noad073.026.

Full text

Abstract:

Abstract Glioma is the most common pediatric central nervous system tumor, with high-grade gliomas (HGG) having one of the worst prognoses of all human cancers. In order to develop better diagnostics and therapies, it is essential to use faithful disease models. Currently, highly passaged patient-derived xenograft (PDX) models are most widely used in preclinical studies, although alternative immunocompetent models are becoming increasingly available. Here, we compare several in vivo glioma models on a single-cell level and investigate their similarity to primary human tumors. Single-nucleus se

APA, Harvard, Vancouver, ISO, and other styles

4

Ahmed, Eman N., Lauren C. Cutmore, and John F. Marshall. "Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells." Cancers 16, no. 18 (2024): 3186. http://dx.doi.org/10.3390/cancers16183186.

Full text

Abstract:

Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of hematological malignancies. Unfortunately, this improvement has yet to be translated into the solid tumor field. Current immunodeficient models used in pre-clinical testing often overestimate the efficacy of CAR T cell therapy as they fail to recapitulate the immunosuppressive tumor microenvironment characteristic of solid tumors. As CAR T cell monotherapy is unlikely to be curative for many solid tumors, combination therapies must be investigated, for example, stromal remodeling agents and immunomodulators. The evalu

APA, Harvard, Vancouver, ISO, and other styles

5

Klose, Johannes, Stefan Trefz, Tobias Wagner, et al. "Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model." PLOS ONE 14, no. 2 (2019): e0211916. http://dx.doi.org/10.1371/journal.pone.0211916.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Weeber, Fleur, Salo N. Ooft, Krijn K. Dijkstra, and Emile E. Voest. "Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery." Cell Chemical Biology 24, no. 9 (2017): 1092–100. http://dx.doi.org/10.1016/j.chembiol.2017.06.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Lulu, Amanda M., Dustin A. Cobb, Nagyeong Park, Lixia Liu, and Daniel W. Lee. "Abstract 6096: Acquired CAR-T therapy resistance in a pre-clinical model of pediatric rhabdomyosarcoma minimal residual disease." Cancer Research 85, no. 8_Supplement_1 (2025): 6096. https://doi.org/10.1158/1538-7445.am2025-6096.

Full text

Abstract:

Abstract Introduction: Current treatments for relapsed/refractory or metastatic rhabdomyosarcoma (RMS) are ineffective. Integrin αvβ3 plays a role in progression, metastasis and neovascularization in several cancers. HER2 is expressed on a majority of RMS and contributes to progression and metastasis in other cancers. Our lab previously demonstrated the efficacy of HER2 and αvβ3 CAR Ts in controlling or eliminating pediatric brain tumors. CAR T therapies for solid tumors face numerous obstacles with limited clinical success. While bispecific CAR Ts can overcome heterogeneous antigen expression

APA, Harvard, Vancouver, ISO, and other styles

8

Serritella, Anthony V., Pablo Saenz-Lopez Larrocha, Payal Dhar, et al. "The Human Soluble NKG2D Ligand Differentially Impacts Tumorigenicity and Progression in Temporal and Model-Dependent Modes." Biomedicines 12, no. 1 (2024): 196. http://dx.doi.org/10.3390/biomedicines12010196.

Full text

Abstract:

NKG2D is an activating receptor expressed by all human NK cells and CD8 T cells. Harnessing the NKG2D/NKG2D ligand axis has emerged as a viable avenue for cancer immunotherapy. However, there is a long-standing controversy over whether soluble NKG2D ligands are immunosuppressive or immunostimulatory, originating from conflicting data generated from different scopes of pre-clinical investigations. Using multiple pre-clinical tumor models, we demonstrated that the impact of the most characterized human solid tumor-associated soluble NKG2D ligand, the soluble MHC I chain-related molecule (sMIC),

APA, Harvard, Vancouver, ISO, and other styles

9

Breen, Kevin, Tuesday Haynes, Masashi Watanabe, and Mark Gilbert. "Abstract 2663: Determining the role of tumor mutational burden in a pre-clinical model of glioblastoma." Cancer Research 84, no. 6_Supplement (2024): 2663. http://dx.doi.org/10.1158/1538-7445.am2024-2663.

Full text

Abstract:

Abstract Despite advances in care in many cancer types, patients with glioblastoma (GBM) have a grim prognosis of 15 to 21 months and unchanged standard therapy since 2005. These tumors have a profoundly immunosuppressive tumor immune microenvironment. Immunotherapy, including the checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4, has transformed the treatment of many cancers but has failed in trials of both newly diagnosed and recurrent GBM. Tumor mutational burden (TMB) has been proposed as a predictor of response to ICI treatment, presumably through an increase in neoantigens that can

APA, Harvard, Vancouver, ISO, and other styles

10

Longe, Harold O., Anupama Sinha, Douglas V. Faller, and Gerald V. Denis. "Telomere-Based Pre-Clinical Therapy of Human Lymphoid Malignancy in a SCID Xenograft Model." Blood 108, no. 11 (2006): 4761. http://dx.doi.org/10.1182/blood.v108.11.4761.4761.

Full text

Abstract:

Abstract We continue to develop and extend our novel adjuvant therapy approach to lymphoid malignancy. We supplement CHOP with DNA oligonucleotides that mimic the chromosomal telomere, which we call a “T oligo.” These agents are homologous to the 3′ overhang nucleotide sequence of telomeres and have previously been shown to have anti-tumor activity in animal models of malignant melanoma and breast cancer. They are currently being evaluated in melanoma and breast cancer patients. If introduced into human or murine normal, proliferating primary B cells or T cells, T oligo causes transient cell c

APA, Harvard, Vancouver, ISO, and other styles

11

Ippagunta, Siri, Erik Emanus, Kelsey Bertrand, and Stephen Mack. "TRLS-16. RAPID GENERATION OF EPENDYMOMA MOUSE MODELS FOR PRE-CLINICAL STUDIES." Neuro-Oncology 25, Supplement_1 (2023): i82. http://dx.doi.org/10.1093/neuonc/noad073.319.

Full text

Abstract:

Abstract Pediatric Ependymomas are the leading cause of cancer death among children & adolescents with the 5-year progression free survival (PFS)rate being &lt; 30%. Despite this poor prognosis there has been less success in development of targeted therapies. A major drawback in developing new therapeutics is lack of proper models of disease. Objective of out work has been to develop orthogonal models of various distinct groups of ependymoma to enable understanding of tumor microenvironment thus leading to strategies targeting potential therapeutic sites. In this regard we have develop

APA, Harvard, Vancouver, ISO, and other styles

12

Boi, Shannon Kathryn, Rachael M. Orlandella, and Lyse A. Norian. "Improving immunotherapeutic efficacy against metastatic tumors in a pre-clinical model of murine renal cell carcinoma." Journal of Immunology 198, no. 1_Supplement (2017): 79.9. http://dx.doi.org/10.4049/jimmunol.198.supp.79.9.

Full text

Abstract:

Abstract Renal and pelvic cancers are the ninth most common cancer in the U.S., and although five-year survival rates for localized renal tumors are &gt;90%, those for metastasized tumors are &lt;12%. Metastatic renal cell carcinoma (RCC), the most common type of renal neoplasm, is resistant to radio- and chemotherapies. Immune-based therapies, including checkpoint blockade, are being pursued in an attempt to amplify protective adaptive immunity but overall response rates remain at 20–30%. We hypothesized that a therapeutic strategy employing T cell priming plus checkpoint blockade wou

APA, Harvard, Vancouver, ISO, and other styles

13

Thomsen, Martin K., and Morten Busk. "Pre-Clinical Models to Study Human Prostate Cancer." Cancers 15, no. 17 (2023): 4212. http://dx.doi.org/10.3390/cancers15174212.

Full text

Abstract:

Prostate cancer is a common cancer among men and typically progresses slowly for several decades before becoming aggressive and spreading to other organs, leaving few treatment options. While large animals have been studied, the dog’s prostate is anatomically similar to humans and has been used to study spontaneous prostate cancer. However, most research currently focuses on the mouse as a model organism due to the ability to genetically modify their prostatic tissues for molecular analysis. One milestone in this research was the identification of the prostate-specific promoter Probasin, which

APA, Harvard, Vancouver, ISO, and other styles

14

Valter, Ann, Tanel Kordemets, Aydan Gasimova, et al. "Pre- and post-operative lung cancer recurrence prediction following curative surgery: A retrospective study using European radiomics and clinical data." Journal of Clinical Oncology 42, no. 16_suppl (2024): 8066. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.8066.

Full text

Abstract:

8066 Background: Accurately estimating the risk of lung cancer recurrence is vital for making informed treatment choices, both before surgery, such as the prescription of neo-adjuvant/peri-operative therapies and the extent of lung resection, and after surgery, such as the prescription of adjuvant therapies and planning follow-up strategies. In this study, we build on previous work demonstrating the predictive power of pre-operative patient demographic and imaging features and develop a machine-learning model using a combination of clinical and tumour radiomic features in the pre- and post-ope

APA, Harvard, Vancouver, ISO, and other styles

15

Fayyad Zaman, Mohammad, Marc Daou, Lynette M. Phillips, et al. "TMIC-46. TRANSCRIPTIONAL HETEROGENEITY AND MECHANISTIC PATHWAYS OF RECURRENT GLIOBLASTOMA: INSIGHTS FROM A PRE-CLINICAL RECURRENT TUMOR MODEL." Neuro-Oncology 26, Supplement_8 (2024): viii308. http://dx.doi.org/10.1093/neuonc/noae165.1224.

Full text

Abstract:

Abstract Despite aggressive therapy combining surgical resection, radiation and chemotherapy, glioblastoma (GBM) almost always recurs. Currently, there is no standard treatment for recurrent GBM, and patient inclusion in clinical trials is based on the genetic and molecular profile of the primary tumor even though the effects of chemoradiation on the transcriptional subtype in matched primary and recurrent GBM remain largely understudied. Paralleling the GLASS consortium, we sought to perform a longitudinal assessment of GBM recurrence after therapy based on molecular subtype with the hypothes

APA, Harvard, Vancouver, ISO, and other styles

16

Gibson, Justin Tyler, Prabhakara Nagareddy, and Lyse A. Norian. "Obesity-induced changes in baseline immune responses to pre-clinical breast cancer." Journal of Immunology 198, no. 1_Supplement (2017): 204.6. http://dx.doi.org/10.4049/jimmunol.198.supp.204.6.

Full text

Abstract:

Abstract Obesity is known to increase morbidity and mortality in breast cancer patients; however, the immunological mechanisms behind these changes remain unclear. The long-term goal of our study is to investigate the broad impact of obesity on anti-tumor immunity, with a particular focus on better understanding immune alterations that may influence the use of immunotherapeutics in breast cancer patients. We began by utilizing the leptin-deficient ob/ob mouse model of obesity and non-obese age matched C57BL/6 controls, in combination with the syngeneic E0771 mammary carcinoma cell line. Tumor

APA, Harvard, Vancouver, ISO, and other styles

17

Iaia, Ilenia, Virginia Brancato, David Caballero, et al. "Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model." Bioengineering 10, no. 1 (2022): 52. http://dx.doi.org/10.3390/bioengineering10010052.

Full text

Abstract:

Adoptive cell therapy in solid tumors, such as melanoma, is impaired, but little is known about the role that the fibroblasts present in the tumor microenvironment could exert. However, the mechanism at play is not well understood, partly due to the lack of relevant pre-clinical models. Three-dimensional culture and microfluidic chips are used to recapitulate the dynamic interactions among different types of cells in the tumor microenvironment in controlled and physiological settings. In this brief report, we propose a reductionist melanoma-on-a-chip model for evaluating the essential role of

APA, Harvard, Vancouver, ISO, and other styles

18

Ciron, Carine, Françoise Shneiker, and Odile Duvaux. "Pre-clinical efficacy of the first glyco-humanized oncolytic polyclonal antibody (XON7) in onco-hematology." Journal of Clinical Oncology 41, no. 16_suppl (2023): e14519-e14519. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e14519.

Full text

Abstract:

e14519 Background: Polyclonal antibodies pAb were shown to possess oncolytic properties a century ago with reported clinical responses. More recent pre-clinical models confirmed pAb efficacy though their ability to tackle complex target antigens. The emergence of escape variants could be minimized by multi-targeting of tumor cells with pAb, which would be more efficient than mAb at mediating effector functions for target destruction. However, the use of heterologous pAb is limited by their immunogenicity. Glyco-humanization (GH) solves this issue and allows to reconsider the potential of pAb i

APA, Harvard, Vancouver, ISO, and other styles

19

ZHOU, FEIFAN, XIAOSONG LI, SHENG SONG, et al. "ANTI-TUMOR RESPONSES INDUCED BY LASER IRRADIATION AND IMMUNOLOGICAL STIMULATION USING A MOUSE MAMMARY TUMOR MODEL." Journal of Innovative Optical Health Sciences 06, no. 04 (2013): 1350039. http://dx.doi.org/10.1142/s1793545813500399.

Full text

Abstract:

Anti-tumor immunological response induced by local intervention is ideal for treatment of metastatic tumors. Laser immunotherapy was developed to synergize photothermal interaction with immunological stimulation for cancer treatment. Using an infrared laser, indocyanine green (ICG, as a light absorbing agent), and glycated chitosan (GC, as an immunostimulant), laser immunotherapy has resulted in tumor suppression and anti-tumor responses in pre-clinical as well as clinical studies. To further understand the mechanism of laser immunotherapy, the effects of laser and GC treatment without specifi

APA, Harvard, Vancouver, ISO, and other styles

20

Bangiev-Girsh, Einav, Amir Basis, Paul Zannou, et al. "Abstract A067: A novel genetically engineered mouse model of ovarian carcinosarcoma." Cancer Research 84, no. 5_Supplement_2 (2024): A067. http://dx.doi.org/10.1158/1538-7445.ovarian23-a067.

Full text

Abstract:

Abstract Ovarian carcinosarcoma (OCS) is a rare and extremely lethal gynecological cancer, accounting for less than 1% of all ovarian cancers, and harboring an unfavorable prognosis compared to the common subtype. There are no efficient treatments available, highlighting the need for a reliable pre-clinical model as a tool to study this disease. Our goal was to generate a genetically engineered mouse model (GEMM) of OCS, carrying relevant genetic alterations, in order to study OCS pathogenesis. To generate the model, we used a Cre-Lox system for targeted knockout of three relevant tumor suppre

APA, Harvard, Vancouver, ISO, and other styles

21

Kines, Rhonda, Reema S. Railkar, Piyush K. Agarwal, and John T. Schiller. "Targeting urothelial neoplasia using an investigational virus-like drug conjugate." Journal of Clinical Oncology 40, no. 6_suppl (2022): 514. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.514.

Full text

Abstract:

514 Background: Human papillomavirus virus-like particles (HPV VLP) preferentially target tumor cells via cell surface modified heparan-sulfate proteoglycans (HSPG). The investigational virus-like drug conjugate, belzupacap sarotalocan (AU-011), is currently in phase 2 clinical trials for treatment of primary choroidal melanoma. We previously demonstrated AU-011’s in vivo tumor acute cytotoxicity upon activation with near-infrared light (nIR), resulting in tumor-free survival for at least 100 days and protection from tumor re-challenge in the MB49 murine flank model of bladder cancer. Here we

APA, Harvard, Vancouver, ISO, and other styles

22

Mihaylov, Ivaylo B., Tulasigeri M. Totiger, Teresa M. Giret, Dazhi Wang, Benjamin Spieler, and Scott Welford. "Toward prediction of abscopal effect in radioimmunotherapy: Pre-clinical investigation." PLOS ONE 16, no. 8 (2021): e0255923. http://dx.doi.org/10.1371/journal.pone.0255923.

Full text

Abstract:

Purpose Immunotherapy (IT) and radiotherapy (RT) can act synergistically, enhancing antitumor response beyond what either treatment can achieve separately. Anecdotal reports suggest that these results are in part due to the induction of an abscopal effect on non-irradiated lesions. Systematic data on incidence of the abscopal effect are scarce, while the existence and the identification of predictive signatures or this phenomenon are lacking. The purpose of this pre-clinical investigational work is to shed more light on the subject by identifying several imaging features and blood counts, whic

APA, Harvard, Vancouver, ISO, and other styles

23

Carr-Ascher, Janai R. "Abstract PR010: Development of a pre-clinical metastatic model of human sarcoma to identify therapeutic targets." Clinical Cancer Research 28, no. 18_Supplement (2022): PR010. http://dx.doi.org/10.1158/1557-3265.sarcomas22-pr010.

Full text

Abstract:

Abstract Targeted therapies have led to significant advances in the treatment of multiple tumor types resulting in more effective and often, less toxic therapeutic options. In sarcomas, the development of targeted therapies has been met limited success. There are more than 70 sarcoma subtypes that vary in histology, clinical course and patient demographics. Despite these clear differences, clinically, sarcomas are treated similarly with variable efficacy. Patients with localized disease are treated with surgery, radiation, and often chemotherapy. Even with this aggressive multimodality treatme

APA, Harvard, Vancouver, ISO, and other styles

24

Gough, Michael J., Lauren Zebertavage, Shelly Bambina, et al. "Anti-tumor immunity generated as an artifact of tumor implantation determines the response to immunotherapy in murine models." Journal of Immunology 200, no. 1_Supplement (2018): 178.17. http://dx.doi.org/10.4049/jimmunol.200.supp.178.17.

Full text

Abstract:

Abstract Cancer cell lines grown in vitro and implanted into mice are a centerpiece of preclinical modeling. However, tumor implantation is an in vivo vaccination event that can impact tumor growth. Checkpoint inhibitors targeting PD1 or CTLA4 interactions are effective at unleashing suppressed pre-existing immunity in murine models, but do not generate new immune responses. We hypothesized that tumor control by checkpoint inhibitor immunotherapies was dependent on pre-existing immunity generated at tumor implantation. Using cancer cells engineered to express model antigens, spontaneous tumor

APA, Harvard, Vancouver, ISO, and other styles

25

Furst, Liam M., Enola M. Roussel, Ryan F. Leung, et al. "The Landscape of Pediatric High-Grade Gliomas: The Virtues and Pitfalls of Pre-Clinical Models." Biology 13, no. 6 (2024): 424. http://dx.doi.org/10.3390/biology13060424.

Full text

Abstract:

Pediatric high-grade gliomas (pHGG) are malignant and usually fatal central nervous system (CNS) WHO Grade 4 tumors. The majority of pHGG consist of diffuse midline gliomas (DMG), H3.3 or H3.1 K27 altered, or diffuse hemispheric gliomas (DHG) (H3.3 G34-mutant). Due to diffuse tumor infiltration of eloquent brain areas, especially for DMG, surgery has often been limited and chemotherapy has not been effective, leaving fractionated radiation to the involved field as the current standard of care. pHGG has only been classified as molecularly distinct from adult HGG since 2012 through Next-Generati

APA, Harvard, Vancouver, ISO, and other styles

26

Gibson, Justin Tyler, Prabhakara Nagareddy, and Lyse Norian. "Obesity-induced changes in baseline immune responses to pre-clinical breast cancer." Journal of Immunology 200, no. 1_Supplement (2018): 177.15. http://dx.doi.org/10.4049/jimmunol.200.supp.177.15.

Full text

Abstract:

Abstract Obesity is known to increase morbidity and mortality in breast cancer patients; however, the immunological contributions to such changes remain incompletely understood. Our long-term goal is to investigate the broad impact of obesity on anti-tumor immunity, with a particular focus on understanding the mechanisms underlying obesity-induced immune alterations and how these alterations may influence the use of immunotherapeutics in breast cancer patients. For our studies, we utilized a diet-induced model of obesity (DIO) in which mice were fed either a high-fat or low-fat diet to generat

APA, Harvard, Vancouver, ISO, and other styles

27

Singh, Naresh, Samantha Sharma, Kevin Van Der Jeught, Zhuolong Zhou, Xinna Zhang, and Xiongbin Lu. "Abstract 119: A non-surgical method for developing a pre-clinical orthotopic mouse model for colorectal cancer." Cancer Research 84, no. 6_Supplement (2024): 119. http://dx.doi.org/10.1158/1538-7445.am2024-119.

Full text

Abstract:

Abstract Recapitulating physiologically relevant tumor microenvironment is important yet a significant challenge in modeling colorectal cancer (CRC) for basic and translational studies. Among the different methods, using the cecal-wall injection technique is the most common way to create animal models of colorectal cancer (CRC). However, this approach requires complex surgery, and its unnatural placement creates a significant obstacle for developing treatments. Here, we report a non-surgical procedure for establishing orthotopic CRC mouse models, reflecting the appropriate tumor microenvironme

APA, Harvard, Vancouver, ISO, and other styles

28

Hagar, A., and J. Aponte Serrano. "P05.02 An integrated virtual tissue platform for incorporating exercise oncology into immunotherapy." Journal for ImmunoTherapy of Cancer 8, Suppl 2 (2020): A41.1—A41. http://dx.doi.org/10.1136/jitc-2020-itoc7.79.

Full text

Abstract:

We introduce a novel in silico platform for simulating solid tumor growth and anti-tumor immune response. We present the model, test the sensitivity and robustness of its parameters, and calibrate it with pre-clinical and clinical data from exercise oncology experiments which offer a natural biological backdrop for modulation of anti-tumor immune response. We then perform two virtual experiments with the model that demonstrate its usefulness in guiding pre-clinical and clinical studies on immunotherapy. The first virtual experiment probes the intricate dynamics in the tumor microenvironment be

APA, Harvard, Vancouver, ISO, and other styles

29

Lindberg, James M., Dustin M. Walters, Sara J. Adair, et al. "Acquired resistance to combination therapy with lapatinib and MEK 1/2 inhibitor GSK1120212 in an in vivo murine model of pancreatic cancer." Journal of Clinical Oncology 30, no. 4_suppl (2012): 208. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.208.

Full text

Abstract:

208 Background: Mutations of the oncogene KRAS and activation of cell-surface receptor tyrosine kinases are important and preserved mechanisms of tumorgenicity in pancreatic cancer. Dual inhibition of the downstream KRAS effector MEK 1/2 and tyrosine kinases EGFR and Her2 results in effective inhibition of patient-derived tumor growth in a murine orthotopic transplantation model. Because combinatorial therapies are moving rapidly into clinical trials, we sought to develop a model of acquired tumor resistance to this combination therapy. Methods: Patient-derived pancreatic tumor xenografts MAD

APA, Harvard, Vancouver, ISO, and other styles

30

Muqbil, Irfana, Mahmoud Chaker, Amro Aboukameel, Ramzi M. Mohammad, Asfar S. Azmi, and Radhakrishanan Ramchandren. "Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model." Heliyon 5, no. 8 (2019): e02290. http://dx.doi.org/10.1016/j.heliyon.2019.e02290.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

McKenna, Mary K., Amanda Rosewell-Shaw, and Masataka Suzuki. "Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives." Cancers 12, no. 3 (2020): 619. http://dx.doi.org/10.3390/cancers12030619.

Full text

Abstract:

Oncolytic adenoviruses (OAd) selectively target and lyse tumor cells and enhance anti- tumor immune responses. OAds have been used as promising cancer gene therapies for many years and there are a multitude of encouraging pre-clinical studies. However, translating OAd therapies to the clinic has had limited success, in part due to the lack of realistic pre-clinical models to rigorously test the efficacy of OAds. Solid tumors have a heterogenous and hostile microenvironment that provides many barriers to OAd treatment, including structural and immunosuppressive components that cannot be modeled

APA, Harvard, Vancouver, ISO, and other styles

32

Modzelewska, K., D. Picard, E. Boer, et al. "PM-12 * USING A ZEBRAFISH PEDIATRIC BRAIN TUMOR MODEL FOR PRE-CLINICAL DRUG SCREENING." Neuro-Oncology 17, suppl 3 (2015): iii33. http://dx.doi.org/10.1093/neuonc/nov061.134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Sypniewska, Roza K., Lieve Hoflack, David J. Bearss, and Claudia Gravekamp. "Potential Mouse Tumor Model for Pre-Clinical Testing of Mage-Specific Breast Cancer Vaccines." Breast Cancer Research and Treatment 74, no. 3 (2002): 221–33. http://dx.doi.org/10.1023/a:1016367104015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kimler, Bruce F. "The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions." Journal of Neuro-Oncology 20, no. 2 (1994): 103–9. http://dx.doi.org/10.1007/bf01052721.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Ramachandran, Indu R., Cindy Lin, Tess Chase, Dmitry Gabrilovich, and Yulia Nefedova. "A Novel Agent Tasquinimod Demonstrates a Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma." Blood 124, no. 21 (2014): 5729. http://dx.doi.org/10.1182/blood.v124.21.5729.5729.

Full text

Abstract:

Abstract Multiple myeloma (MM) is a devastating bone marrow (BM) cancer characterized by clonal proliferation of plasma cells. Despite the emergence of novel therapeutics MM remains a fatal disease. The tumor microenvironment plays a critical role in promoting MM growth. We have recently demonstrated that a population of BM myeloid-derived suppressor cells is involved in regulation of MM progression. These cells abundantly produce the pro-inflammatory protein S100A9. Tasquinimod (ABR-215050, Active Biotech/IPSEN) is a quinoline-3-carboxamide derivative that binds to S100A9 and blocks its inter

APA, Harvard, Vancouver, ISO, and other styles

36

Haddad, Alexander, Jordan Spatz, Sara Collins, et al. "EXTH-17. LOCAL DELIVERY OF CYTOKINES AND SYNTHETIC IMMUNOMODULATORS INCREASES T CELL INFILTRATION AND SIGNIFICANTLY IMPROVES SURVIVAL IN A POORLY IMMUNOGENIC MODEL OF GLIOBLASTOMA." Neuro-Oncology 22, Supplement_2 (2020): ii90. http://dx.doi.org/10.1093/neuonc/noaa215.371.

Full text

Abstract:

Abstract BACKGROUND Severe local and systemic immune suppression in glioblastoma (GBM) contributes to the failure of single-agent immunotherapies in clinical trials. In this study, we evaluated the efficacy of locally delivered combination immunotherapy in a poorly immunogenic murine GBM model. METHODS Immunomodulators used in these studies included: IL-15 and IL-7 (T cell activation), LIGHT (T cell tumor infiltration), FLT3L (dendritic cell maturation/proliferation), a surface T cell engager (T cell killing of tumor cells), and a bispecific PD-L1/T cell engager (T cell killing targeted to PD-

APA, Harvard, Vancouver, ISO, and other styles

37

Huang, Wentao, Zhifang Liu, Yifan Li, et al. "Abstract 5907: Pre-clinical evaluation of a novel antibody drug conjugate (ADC) LM-317 targeting NaPi2b." Cancer Research 84, no. 6_Supplement (2024): 5907. http://dx.doi.org/10.1158/1538-7445.am2024-5907.

Full text

Abstract:

Abstract Introduction: NaPi2b is a multi-transmembrane type II sodium-dependent phosphate transporters that regulates phosphate homeostasis in normal physiological condition [1]. It is highly expressed in ovarian cancer (OC), non-small-cell lung cancer (NSCLC), and papillary thyroid cancer, with limited expression in normal tissue, making it a promising target for antibody-drug conjugates (ADCs) [2,3]. LM-317 is a novel NaPi2b targeted humanized monoclonal antibody LM-117 conjugated to the next-generation topoisomerase I inhibitor LDX2 via a cleavable linker, with antibody-drug ratio of 8. Her

APA, Harvard, Vancouver, ISO, and other styles

38

Bownes, Laura, Raoud Marayati, Colin Quinn, et al. "Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma." Cancers 14, no. 8 (2022): 1952. http://dx.doi.org/10.3390/cancers14081952.

Full text

Abstract:

Background: Protein phosphatase 2A (PP2A) functions as an inhibitor of cancer cell proliferation, and its tumor suppressor function is attenuated in many cancers. Previous studies utilized FTY720, an immunomodulating compound known to activate PP2A, and demonstrated a decrease in the malignant phenotype in neuroblastoma. We wished to investigate the effects of two novel PP2A activators, ATUX-792 (792) and DBK-1154 (1154). Methods: Long-term passage neuroblastoma cell lines and human neuroblastoma patient-derived xenograft (PDX) cells were used. Cells were treated with 792 or 1154, and viabilit

APA, Harvard, Vancouver, ISO, and other styles

39

Sauvage, Delphine, Manon Bosseler, Elodie Viry, et al. "The BET Protein Inhibitor JQ1 Decreases Hypoxia and Improves the Therapeutic Benefit of Anti-PD-1 in a High-Risk Neuroblastoma Mouse Model." Cells 11, no. 18 (2022): 2783. http://dx.doi.org/10.3390/cells11182783.

Full text

Abstract:

Anti-programmed death 1 (PD-1) is a revolutionary treatment for many cancers. The response to anti-PD-1 relies on several properties of tumor and immune cells, including the expression of PD-L1 and PD-1. Despite the impressive clinical benefit achieved with anti-PD-1 in several cancers in adults, the use of this therapy for high-risk neuroblastoma remains modest. Here, we evaluated the therapeutic benefit of anti-PD-1 in combination with JQ1 in a highly relevant TH-MYCN neuroblastoma transgenic mouse model. JQ1 is a small molecule inhibitor of the extra-terminal domain (BET) family of bromodom

APA, Harvard, Vancouver, ISO, and other styles

40

Nayyar, Naema, Magali de Sauvage, Emily Sullivan, et al. "DDDR-02. CDK4/6 INHIBITION WITH ABEMACICLIB SENSITIZES INTRACRANIAL TUMORS TO CHECKPOINT BLOCKADE IN PRE-CLINICAL MODELS OF BRAIN METASTASIS." Neuro-Oncology 24, Supplement_7 (2022): vii98. http://dx.doi.org/10.1093/neuonc/noac209.367.

Full text

Abstract:

Abstract Although immune checkpoint inhibitors (ICI) have become a useful tool in the management of central nervous system (CNS) metastases, only a subset of patients experience durable clinical responses and prognosis continues to remain poor. In particular, the role of ICI for CNS metastases from breast cancer has also not been adequately explored. CDK4/6 inhibition has been shown to sensitize extracranial tumors to ICI, and we previously reported intracranial efficacy of combination CDK4/6 inhibition with abemaciclib and anti-PD-1 in preclinical models of melanoma brain metastasis. We have

APA, Harvard, Vancouver, ISO, and other styles

41

Chen, Chao-Yi, Yi-Feng Yang, Paul C. Wang, et al. "Simvastatin Attenuated Tumor Growth in Different Pancreatic Tumor Animal Models." Pharmaceuticals 15, no. 11 (2022): 1408. http://dx.doi.org/10.3390/ph15111408.

Full text

Abstract:

Newly diagnosed pancreatic cancer increases year by year, while the prognosis of pancreatic cancer has not been very good. Statin drugs were found to have protective effects against a variety of cancers, but their association with pancreatic cancer remains to be clarified. This study used different pancreatic cancer cell lines and in different animal models to confirm the relationship between simvastatin and pancreatic cancer. Flow cytometry and luciferase-based bioluminescent images were used to investigate the cell cycle and tumor growth changes under simvastatin treatment. Simvastatin decre

APA, Harvard, Vancouver, ISO, and other styles

42

Zhao, Yonghao, Pengfei Ren, Menglong Guan, et al. "Abstract 1585: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model." Cancer Research 85, no. 8_Supplement_1 (2025): 1585. https://doi.org/10.1158/1538-7445.am2025-1585.

Full text

Abstract:

TROP2 (trophoblast cell surface antigen 2) is expressed at high levels in various human carcinomas and is associated with tumor differentiation and pathological aggression. Several antibody-drug conjugates (ADCs) targeting TROP2, such as sacituzumab govitecan and datopotamab deruxtecan, have shown promising anti-tumor activity in multiple solid tumors, particularly in breast cancer. However, their clinical application remains limited by inadequate efficacy, highlighting the unmet clinical need for improving the efficacy of single payload TROP2-targeting ADCs.This study presents the preclinical

APA, Harvard, Vancouver, ISO, and other styles

43

Zhao, Yonghao, Pengfei Ren, Menglong Guan, et al. "Abstract 1586: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model." Cancer Research 85, no. 8_Supplement_1 (2025): 1586. https://doi.org/10.1158/1538-7445.am2025-1586.

Full text

Abstract:

Abstract TROP2 (trophoblast cell surface antigen 2) is expressed at high levels in various human carcinomas and is associated with tumor differentiation and pathological aggression. Several antibody-drug conjugates (ADCs) targeting TROP2, such as sacituzumab govitecan and datopotamab deruxtecan, have shown promising anti-tumor activity in multiple solid tumors, particularly in breast cancer. However, their clinical application remains limited by inadequate efficacy, highlighting the unmet clinical need for improving the efficacy of single payload TROP2-targeting ADCs.This study presents the pr

APA, Harvard, Vancouver, ISO, and other styles

44

Severe, Nicolas, Amanda Facklam, Liz McMichael, et al. "Abstract 742: PYX-201, a stroma-targeting ADC composed of an anti-EDB+FN antibody conjugated to Auristatin0101, demonstrates strong anti-tumor efficacy across multiple human cancer indications in pre-clinical PDX tumor models." Cancer Research 84, no. 6_Supplement (2024): 742. http://dx.doi.org/10.1158/1538-7445.am2024-742.

Full text

Abstract:

Abstract Stroma is crucial to support solid tumor growth, metastasis and resistance to treatment. While most antibody-drug conjugates (ADCs) directly bind to cancer cells, PYX-201, an investigational drug, is designed to target tumor stroma by binding to the extra-domain B splice variant of fibronectin (EDB+FN), a matrix protein abundantly expressed in the tumor microenvironment of many solid tumors with absent or low expression in normal adult tissues. In vitro studies demonstrated PYX-201 was strongly cytotoxic to EDB+FN positive Caki2 cells, but not to EDB+FN negative HT29 cells. In additio

APA, Harvard, Vancouver, ISO, and other styles

45

Tatalick, Laurie, Kevin Yu, Justin Huard, et al. "898 Intratumoral administration of NL-201, an alpha-independent IL-2/15 receptor agonist, inhibits the growth of both injected and uninjected tumors in preclinical models." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (2021): A942. http://dx.doi.org/10.1136/jitc-2021-sitc2021.898.

Full text

Abstract:

BackgroundNL-201 is a potent, selective, and long-acting computationally designed alpha-independent agonist of the IL-2 and IL-15 receptors that is being developed as an immunotherapy for cancer. Intravenous NL-201 administration is active in numerous pre-clinical tumor models. Here, we report data demonstrating favorable tolerability, pharmacokinetics, and antitumor activity of NL-201 after intratumoral (IT) administration in syngeneic murine tumor models.MethodsMice were implanted with syngeneic colorectal tumors in a single tumor (right flank) or bilateral tumor model (right and left flank)

APA, Harvard, Vancouver, ISO, and other styles

46

Connor, Kate, Emer Conroy, Kieron White, et al. "EXTH-30. EXPANDING THE UTILITY OF PRE-CLINICAL CONTRAST ENHANCED CT (CE-CT) FOR TUMOR DETECTION IN ORTHOTOPIC GBM MODELS USING RADIOMICS." Neuro-Oncology 22, Supplement_2 (2020): ii93. http://dx.doi.org/10.1093/neuonc/noaa215.384.

Full text

Abstract:

Abstract Despite magnetic resonance imaging (MRI) being the gold-standard imaging modality in the glioblastoma (GBM) setting, the availability of rodent MRI scanners is relatively limited. CT is a clinically relevant alternative which is more widely available in the pre-clinic. To study the utility of contrast-enhanced (CE)-CT in GBM xenograft modelling, we optimized CT protocols on two instruments (IVIS-SPECTRUM-CT;TRIUMPH-PET/CT) with/without delivery of contrast. As radiomics analysis may facilitate earlier detection of tumors by CT alone, allowing for deeper analyses of tumor characteristi

APA, Harvard, Vancouver, ISO, and other styles

47

McCully, Cynthia Lester, Katherine Warren, Sara Zimmerman, et al. "EXTH-64. COMPARISON OF PANOBINOSTAT CSF PENETRATION WITH CNS PENETRATION FOLLOWING SYSTEMIC ADMINISTRATION IN A PRE-CLINICAL NON-HUMAN PRIMATE MODEL." Neuro-Oncology 23, Supplement_6 (2021): vi177—vi178. http://dx.doi.org/10.1093/neuonc/noab196.703.

Full text

Abstract:

Abstract Targeted therapies developed for diffuse midline gliomas (DMG) expressing H3K27M have focused on histone deacetylase inhibitors (HDACi). High-throughput drug screening with patient derived DMG cell lines identified the HDACi panobinostat as a prominent clinical agent as well as pre-clinical studies with orthotopic mouse tumors models proving efficacious. Diametrically there is a pronounced lack of measurable panobinostat CSF concentrations in a non-human primate (NHP) non-tumor bearing pre-clinical model and in pediatric brain tumor patients. Notwithstanding, adult and pediatric gliom

APA, Harvard, Vancouver, ISO, and other styles

48

Roth, Daniel, Marcella Safi, Oskar Vilhelmsson Timmermand, et al. "Evaluation of superficial xenograft volume estimation by ultrasound and caliper against MRI in a longitudinal pre-clinical radiotherapeutic setting." PLOS ONE 19, no. 7 (2024): e0307558. http://dx.doi.org/10.1371/journal.pone.0307558.

Full text

Abstract:

Background Accurate tumor volume estimation is important for evaluating the response to radionuclide therapy and external beam radiotherapy as well as to other pharmaceuticals. A common method for monitoring the growth of subcutaneous tumors in pre-clinical models and assessing the treatment response is to measure the tumor length and width by external calipers to estimate its volume. This procedure relies on an assumption of a spheroidal tumor shape wherein the tumor depth equals the width and can yield considerably inaccuracies. Ultrasound imaging is a non-invasive technique that can measure

APA, Harvard, Vancouver, ISO, and other styles

49

Jervis, Luke, Yuan-Hung Chien, Warren Andrews, Raffaella Pippa, and Long Do. "Abstract LB344: CertisOI Assistant™ - Accelerating Preclinical Cancer Model Selection with Generative AI." Cancer Research 85, no. 8_Supplement_2 (2025): LB344. https://doi.org/10.1158/1538-7445.am2025-lb344.

Full text

Abstract:

Abstract Pre-clinical oncology researchers face significant challenges when identifying suitable tumor models. Suboptimal model selection can impede the translational success of preclinical findings to clinical applications. Traditional online databases rely on rigid filtering systems that may not accommodate the complex and specific criteria researchers require. To address this critical need, Certis Oncology developed CertisOI, a Generative AI-powered platform that transforms how researchers discover and analyze cancer tumor models for their studies. CertisOI functions as an interactive resea

APA, Harvard, Vancouver, ISO, and other styles

50

Andrejeva, Gabriela, Benjamin Capoccia, Rachel Delston, et al. "260 CD47 antibody, AO-176 demonstrates potent anti-tumor activity in pre-clinical solid tumor xenografts as a single agent and in combination with multiple classes of therapeutics." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (2021): A282. http://dx.doi.org/10.1136/jitc-2021-sitc2021.260.

Full text

Abstract:

BackgroundCD47 is a cell surface protein expressed on tumors that binds SIRPα on macrophages and dendritic cells resulting in a ”don’t eat me” signal that allows tumors to evade phagocytosis. The highly differentiated monoclonal antibody, AO-176 directly targets CD47 and blocks this signal. AO-176 is currently being tested in phase 1 clinical trials in solid tumors and multiple myeloma. The purpose of this study was to assess in vivo efficacy of AO-176 in solid tumor models as a single agent and in combination with multiple classes of therapeutics including chemotherapeutics, monoclonal antibo

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!